Astrazeneca plc (AZN)
Income statement / Yearly
Dec'17Dec'16Dec'15
Product Sales

20,152

21,319

23,641

Externalisation Revenue

2,313

1,683

1,067

Total Revenue

22,465

23,002

24,708

Cost of sales

4,318

4,126

4,646

Gross profit

18,147

18,876

20,062

Distribution costs

310

326

339

Research and development expense

5,757

5,890

5,997

Selling, general and administrative costs

10,233

9,413

11,112

Other operating income & expense

1,830

1,655

1,500

Operating profit

3,677

4,902

4,114

Finance income

113

67

46

Finance expense

1,508

1,384

1,075

Share of after tax losses in associates and joint ventures

-55

-33

-16

Profit before tax

2,227

3,552

3,069

Taxation

-641

146

243

Profit for the period

2,868

3,406

2,826

Other comprehensive income:
Remeasurement of the defined benefit pension liability

-242

-575

652

Fair value movements related to own credit risk on bonds designated as fair value through profit or loss

-9

-

-

Tax on items that will not be reclassified to profit or loss

-16

-136

199

Total other comprehensive income that will not be reclassified to profit or loss, net of tax

-235

-439

453

Foreign exchange arising on consolidation

536

-1,050

-528

Foreign exchange arising on designating borrowings in net investment hedges

505

-591

-333

Fair value movements on cash flow hedges

311

-115

-

Fair value movements on cash flow hedges transferred to profit or loss

315

-195

-

Fair value movements on derivatives designated in net investment hedges

-48

-4

14

Amortisation of loss on cash flow hedge

-1

-1

-1

Net available for sale gains/(losses) taken to equity

-83

139

-32

Tax on items that may be reclassified subsequently to profit or loss

33

-86

-87

Total other comprehensive income that will be reclassified to profit or loss, net of tax

874

-1,339

-791

Other comprehensive (loss) / income for the period, net of tax

639

-1,778

-338

Total comprehensive income for the period

3,507

1,628

2,488

Owners of the Parent

3,001

3,499

2,825

Non-controlling interests

-133

-93

1

Total comprehensive income attributable to:
Owners of the Parent

3,640

1,722

2,488

Non-controlling interests

-133

-94

-

Basic earnings loss per (in dollars per share)

2.37

2.77

2.23

Diluted earnings loss per Share (in dollars per share)

2.37

2.76

2.23

Weighted average number of Ordinary Shares in issue for basic earnings

1,266

1,265

1,264

Diluted weighted average number of Ordinary Shares in issue (millions)

1,267

1,266

1,265

Dividends declared and paid in the period

3,543

3,540

3,537